Alan Gordon, MD
Retina Specialist · Phoenix, AZNPI 1518959287
Payments from drug & device makers
What this record shows
The money is spread across several categories — other (58.2%), ownership interests and food and beverage — rather than concentrated in one kind of arrangement. US Retina LLC accounts for 96.3% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2024 at $50,810 and has fallen 99.5% since, to $268 in 2025.
Across 72 payments — averaging $1193.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- US Retina LLC$83K
- Genentech USA, Inc.$529
- Bausch & Lomb Americas Inc.$454
- Regeneron Healthcare Solutions, Inc.$451
- Dutch Ophthalmic, USA$322
- AbbVie$322
- plus $1K from 9 others
Across 150 payments — averaging $7434.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$691K
- Novartis$409K
- Mylan Technologies Inc.$8K
- Mylan Inc.$7K
What the payments were for
- Food & beverage$3,5424%
- Gifts$390%
- Ownership interest$32,38338%
- Other$50,00058%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| US Retina LLC | 9 | $82,825 |
| Genentech USA, Inc. | 20 | $529 |
| Bausch & Lomb Americas Inc. | 4 | $454 |
| Regeneron Healthcare Solutions, Inc. | 13 | $451 |
| Dutch Ophthalmic, USA | 2 | $322 |
| AbbVie(2 entities) | 7 | $322 |
| Alimera Sciences, Inc. | 1 | $316 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $262 |
| Novartis | 5 | $176 |
| Eyepoint US, Inc. | 1 | $109 |
| Astellas Pharma US Inc | 2 | $50 |
| Regeneron | 1 | $44 |
| Carl Zeiss Meditec AG | 2 | $39 |
| Apellis Pharmaceuticals, Inc. | 2 | $34 |
| Coherus Oncology, Inc. | 1 | $29 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- STELLARIS$433
- YUTIQ$425
- Iluvien$316
- STELLARIS PC$262
- EVA Ophthalmic Surgical System$172
- VABYSMO$154
- EVA, combined machine$151
- EYLEA$106
- OZURDEX$102
How this compares
$85,964 in reported general payments places this provider in the 75th percentile of 30 retina specialist providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 231 | $12,319 |
| Brimonidine Tartrate | 67 | $5,801 |
| ProlensaBromfenac Sodium | 12 | $4,208 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 77 | $1,552 |
| Ofloxacin | 111 | $1,201 |
| Latanoprost | 59 | $570 |
| Dorzolamide Hcl | 25 | $412 |
| Timolol Maleate | 25 | $112 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $262 | $4,20812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 30 retina specialist providers in Arizona.
Other retina specialist in Phoenix
- Jordan GraffPhoenix$483K
- Rahul ReddyPhoenix$333K
- Henry KwongPhoenix$147K
- Benjamin BakallPhoenix$137K
- Jaime GaitanPhoenix$114K
- Stephen de SouzaPhoenix$95K
- Joseph BryanPhoenix$88K
- Suhail AlamPhoenix$24K
- Rima PatelPhoenix$19K
- Matthew WelchPhoenix$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.